EUVIMEDEUVIMED entdecken
Crossref

A novel approach to induce early remission in high-risk primary membranous nephropathy

Zinaida Kochoyan iD, Vladimir A Dobronravov iD

Nephrology Dialysis Transplantation · 2024

DOI: 10.1093/ndt/gfae138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Zinaida Kochoyan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Nephrology, Pavlov University, Saint Petersburg, Russian Federation. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Remission Induction, Immunosuppressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Dokuchaev Soil Science Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This prospective single-arm trial with historic controls evaluated the efficacy and safety of treatment based on a combination of rituximab, intravenous cyclophosphamide and corticosteroids (RCP) administered at lower cumulative doses for the induction of early remission in primary membranous nephropathy (PMN).

Methods

We prospectively enrolled 30 high-risk PMN patients with persistent nephrotic syndrome (NS) and elevated antibodies to the phospholipase A2 receptor who underwent RCP therapy. We compared the effectiveness of RCP with that of historic controls who received rituximab-based therapy (RTX, n = 15) or cyclosporine + corticosteroids (CSA, n = 42). The primary outcomes were complete remission (CR) and overall remission (OR) by Month 12 and the time to remission.

Results

In the RCP group, the OR and CR rates by 12 months (97% and 60%) were higher than those in the RTX group (60% and 7%, P ≤ .009) and the CSA group (50% and 24%, P ≤ .003). The median time to OR [2.8 (1.6–3.9) months] was shorter compared with RTX [7.1 (3.4–17.5) months, P = .008] and CSA [7.3 (6.0–13.6) months, P < .001]. In adjusted Cox regression, hazard ratios for OR and CR attainment for RCP versus other treatments were 5.2 (95% CI 2.8–9.6) and 4.8 (95% CI 2.2–10.3), respectively. Propensity score–matched group analyses confirmed these results. One serious adverse event occurred in the RCP group in the follow-up of 56 patient-years.

Conclusions

RCP therapy is considered effective and safe for inducing early remission in high-risk PMN patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousRemission InductionImmunosuppressive AgentsHumansMaleFemaleMiddle AgedProspective StudiesFollow-Up StudiesAdultRituximabDrug Therapy, CombinationCyclophosphamidePrognosisAdrenal Cortex HormonesCase-Control StudiesReceptors, Phospholipase A2

Stichwörter der Autor:innen

corticosteroidscyclophosphamideearly remissionprimary membranous nephropathyrituximab

Substanzen

Immunosuppressive AgentsRituximabCyclophosphamideAdrenal Cortex HormonesReceptors, Phospholipase A2

Autor:innen und Institutionen

  • Research Institute of Nephrology, Pavlov University, Saint Petersburg, Russian Federation.

ORCID-Profile: Zinaida Kochoyan, Vladimir A Dobronravov

Förderung

  • Dokuchaev Soil Science Institute

Zitieren

APA

Kochoyan, Z., & Dobronravov, V. A. (2024). A novel approach to induce early remission in high-risk primary membranous nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae138

Vancouver

Kochoyan Z, Dobronravov VA. A novel approach to induce early remission in high-risk primary membranous nephropathy. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfae138

BibTeX
@article{Kochoyan2024,
  author = {Kochoyan, Zinaida and Dobronravov, Vladimir A},
  title = {A novel approach to induce early remission in high-risk primary membranous nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  doi = {10.1093/ndt/gfae138}
}
Kostenlos starten →